ARCALIS Completes Construction of New mRNA Drug Product Manufacturing Facility
ARCALIS, Inc. (Headquarters: Minamisoma City, Fukushima Prefecture; “ARCALIS”) today announced the completion of its new mRNA drug product manufacturing facility (“DP Facility”) in Minamisoma City, Fukushima Prefecture, on February 27, 2026.
The DP Facility operates under a quality management system aligned with international GMP standards. With the addition of this facility to ARCALIS’s Kashiwanoha Site and the Drug Substance Facility at the Minamisoma Site (completed in July 2023), ARCALIS is now positioned to provide fully integrated services spanning from research and development through commercial manufacturing of mRNA therapeutics and vaccines.
ARCALIS remains committed to delivering efficient, high-quality manufacturing solutions, and to meeting the diverse needs of its customers.
<Description>
| Name | ARCALIS Minamisoma Drug Product Manufacturing Facility |
| Address | 320-20 Kawauchisaku, Shimoota aza, Haramachi, Minamisoma, Fukushima 975-0041 |
| Structure | Five-story steel-frame building with seismic isolation (36 meters in height) |
| Building Area | 2,260 m² |
| Total Floor Area | 9,140 m² |
| Facility Overview | The facility features advanced manufacturing capabilities for the production of mRNA therapeutics and vaccines. It operates under a quality management system aligned with international GMP standards, enabling supply to global markets. |
| Manufacturable Products | mRNA therapeutics and vaccines (LNP drug substance; liquid and lyophilized vial presentations) |
| Production Capability | 32 million doses per year |
| Construction, Design, and Project Management | Obayashi Corporation |
<Outside View >
Photo